Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients... Details
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia Calquence (acalabrutinib) is a 2nd generation BTK inhibitor with a different side effect profile than ibrutinib. It is already approved... Details
NICE okays chemotherapy-free combination venetoclax plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL) NICE gives green light for chemotherapy-free combination of venetoclax plus obinutuzumab for all front-line patients with CLL ... Details
The LLS CLL Co-Pay Assistance Fund is Open! LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are... Details
FDA Grants Fast Track Designation to Ublituximab Plus Umbralisib in Chronic Lymphocytic Leukemia With this fast track designation, the combination of ublituximab and umbralisib should move through the FDA's approval process more quickly,... Details
New approval for venetoclax for Acute Myeloid Leukemia (AML) The U.S. Food and Drug Administration (FDA) has granted full approval of venetoclax in combination with azacitidine, or decitabine, or... Details
FDA Clearance for clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia (CLL) This is good news for CLL patients as measurement for MRD (minimal or measurable residual disease) is increasingly being recognized... Details
Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical... Details
Proposed Changes to Reimbursement to Help Pay for CAR-T Therapy for Patients Covered by Medicare or Medicaid May 15, 2020 CAR-T is an essential new treatment opportunity for patients. In my personal experience, I have no measurable leukemia... Details
A Petition to CMS for Medicare Reimbursement for Use of CAR-T CAR-T is a potent and helpful option for many blood cancer patients, but Medicare and Medical insurance coverage can be... Details
